Aileron Therapeutics (ALRN)
(Delayed Data from NSDQ)
$3.73 USD
+0.82 (28.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.83 +0.10 (2.68%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Aileron Therapeutics, Inc. [ALRN]
Reports for Purchase
Showing records 1 - 20 ( 42 total )
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Aileron Terminates Phase 1b Breast Cancer Chemoprotection Study; Exploring Strategic Alternatives
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Initial Phase 1b Breast Cancer Data Could be Announced This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Findings From Phase 1 Study of ALRN-6924 in Healthy Volunteers Presented at EORTC-NCI-AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Phase 1b Breast Cancer Study to Reinstate Enrollment in the Coming Weeks
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrade to Neutral Following Challenges and Changes For ALRN-6924 Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Disappointing Data for ALRN-6924; Exiting NSCLC Space; Cutting Price Target in Half
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Investor Event Highlights; Three Important Data Readouts Remaining in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Interim Phase 1b ALRN-6924 Data in NSCLC Patients Expected Next Month
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Interim ALRN-6924 Data Expected Next Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Business Update; New Phase 1b Study of ALRN-6924 in Neoadjuvant Breast Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; NSCLC Phase 1b Study Data Timing Slightly Delayed Due to the COVID Pandemic
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ALRN-6924 Healthy Volunteer Data and Final SCLC Results at ESMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Findings From Healthy Volunteer Study With ALRN-6924
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; ALRN-6924 in NSCLC Interim Safety Data Expected by YE21, Top-line Results in Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ALRN-6924 Trial in Advanced Non-Small Cell Lung Cancer Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; ALRN-6924 Phase 1b Trial Expected to Initiate This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Results; Interim Phase 1b Data for ALRN-6924 Expected by YE21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Aileron Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Business Update; Direct Offering and ATM Remove Financial Overhang
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E